IP Library › Granted Patent US 12,195,547
Granted Patent B2
US 12,195,547 · App. 17/733,918 · Granted Jan 14, 2025

Dosing for combination treatment with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate

Inventors: Katharina Lechner (Munich, DE); Thomas Francis Moore (Starnberg, DE); Martin Weisser (Penzberg, DE); Natalie Dimier (Welwyn Garden City, GB); David John Carlile (Princes Riborough, GB); Nassim Djebli (Rixheim, FR); Peter Nabil Morcos (Marlboro, NJ); Linda Maria Lundberg (Binningen, CH)
Assignee: Hoffmann-La Roche Inc.
C07K16/2887A61K47/68031A61K47/6849A61P35/00C07K16/2803C07K16/2809A61K2039/507A61K2039/545C07K2317/24C07K2317/31C07K2317/35C07K2317/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,547
App. No.
17/733,918
Granted
Jan 14, 2025
Kind
B2
Abstract

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.

Claims (77)

1. A method of treating a subject having a CD20-positive cell proliferative disorder comprising administering to the subject polatuzumab vedotin and glofitamab in a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein:

(a) the first dosing cycle comprises:

(i) a single dose (C1D1) of polatuzumab vedotin administered on Day 2 of the first dosing cycle; and

(ii) a first dose (C1D1) of glofitamab administered on Day 8 of the first dosing cycle and a second dose (C1D2) of glofitamab administered on Day 15 of the first dosing cycle, wherein the C1D1 of glofitamab is about 2.5 mg, and the C1D2 of glofitamab is about 10 mg; and

(b) the second dosing cycle comprises:

(i) a single dose (C2D1) of polatuzumab vedotin administered on Day 1 of the second dosing cycle; and

(ii) a single dose (C2D1) of glofitamab administered on Day 1 of the second dosing cycle, wherein the C2D1 of glofitamab is about 30 mg, and the C1D1 and C2D1 of polatuzumab vedotin are each about 1.8 mg/kg.

2. A method of treating a subject having a CD20-positive cell proliferative disorder comprising administering to the subject polatuzumab vedotin and glofitamab in a dosing regimen comprising 12 dosing cycles, wherein:

(a) the first dosing cycle comprises a first dose (C1D1) of glofitamab administered on Day 8 of the first dosing cycle, a second dose (C1D2) of glofitamab administered on Day 15 of the first dosing cycle, and a single dose (C1D1) of polatuzumab vedotin administered on Day 2 of the first dosing cycle, wherein the C1D1 of glofitamab is about 2.5 mg, and the C1D2 of glofitamab is about 10 mg;

(b) the second to sixth dosing cycles each comprises a single dose (C2D1-C6D1) of glofitamab and a single dose (C2D1-C6D1) of polatuzumab vedotin; and

(c) the seventh to 12th dosing cycles each comprises a single dose (C7D1-C12D1) of glofitamab and does not comprise administration of polatuzumab vedotin,

wherein each single dose C2D1-C12D1 of glofitamab is administered on Day 1 of each dosing cycle, and each single dose C2D1-C6D1 of polatuzumab vedotin is administered on Day 1 of each dosing cycle, and wherein each single dose C2D1-C12D1 of glofitamab is about 30 mg and each single dose C1D1-C6D1 of polatuzumab vedotin is about 1.8 mg/kg.

3. The method of claim 2 , wherein:

(a) the dosing cycles are 21-day dosing cycles;

(b) glofitamab is administered intravenously; and/or

(c) polatuzumab vedotin is administered intravenously.

4. The method of claim 2 , wherein the method further comprises administering to the subject obinutuzumab.

5. The method of claim 4 , wherein obinutuzumab is administered:

(a) prior to administration of glofitamab; and/or

(b) as a single dose of about 1000 mg.

6. The method of claim 5 , wherein obinutuzumab is administered about seven days prior to administration of glofitamab.

7. The method of claim 2 , wherein the CD20-positive cell proliferative disorder is a B cell proliferative disorder.

8. The method of claim 7 , wherein the B cell proliferative disorder is a non-Hodgkin's lymphoma (NHL) or a central nervous system lymphoma (CNSL).

9. The method of claim 8 , wherein the NHL is:

(a) relapsed and/or refractory; and/or

(b) a diffuse-large B cell lymphoma (DLBCL), a follicular lymphoma (FL), a mantle cell lymphoma (MCL), a marginal zone lymphoma (MZL), a high-grade B cell lymphoma, a primary mediastinal (thymic) large B cell lymphoma (PMLBCL), a diffuse B cell lymphoma, or a small lymphocytic lymphoma.

10. The method of claim 7 , wherein the B cell proliferative disorder is relapsed and/or refractory.

11. A method of treating a population of subjects having a relapsed and/or refractory NHL comprising administering to the subjects polatuzumab vedotin and glofitamab in a dosing regimen comprising 12 dosing cycles, wherein:

(a) the first dosing cycle comprises:

(i) a first dose (C1D1) of glofitamab administered on Day 8 of the first dosing cycle and a second dose (C1D2) of glofitamab administered on Day 15 of the first dosing cycle, wherein the C1D1 of glofitamab is about 2.5 mg, and the C1D2 of glofitamab is about 10 mg; and

(ii) a single dose (C1D1) of polatuzumab vedotin administered on Day 2 of the first dosing cycle;

(b) the second to sixth dosing cycles each comprises a single dose (C2D1-C6D1) of glofitamab and a single dose (C2D1-C6D1) of polatuzumab vedotin; and

(c) the seventh to 12th dosing cycles each comprises a single dose (C7D1) of glofitamab and does not comprise administration of polatuzumab vedotin, and

wherein each single dose C2D1-C12D1 of glofitamab is administered on Day 1 of each dosing cycle, and each single dose C2D1-C6D1 of polatuzumab vedotin is administered on Day 1 of each dosing cycle, and wherein each single dose C2D1-C12D1 of glofitamab is about 30 mg and each single dose C1D1-C6D1 of polatuzumab vedotin is about 1.8 mg/kg.

12. The method of claim 11 , wherein:

(a) the complete response rate is at least 20%; and/or

(b) the overall response rate is at least 30%.

13. The method of claim 11 , wherein:

(a) the relapsed and/or refractory NHL is a relapsed and/or refractory MCL; and wherein:

(i) the complete response rate is at least 60%; and/or

(ii) the overall response rate is at least 60%; or

(b) the NHL is a relapsed and/or refractory DLBCL; and wherein:

(i) the complete response rate is at least 35%; and/or

(ii) the overall response rate is at least 60%.

14. The method of claim 11 , wherein:

(a) the complete response rate is higher than a reference complete response rate in a reference population of subjects treated with a combination therapy comprising glofitamab and atezolizumab and not comprising polatuzumab vedotin; and/or

(b) the objective response rate is higher than a reference objective response rate in a reference population of subjects treated with a combination therapy comprising glofitamab and atezolizumab and not comprising polatuzumab vedotin.

15. The method of claim 2 , wherein the C2D1-C12D1 of glofitamab is administered after the administration of the C2D1-C12D1 of polatuzumab vedotin has completed.

16. The method of claim 2 , wherein the subject:

(a) is human;

(b) has received at least two prior systemic therapies; and/or

(c) is ineligible for autologous stem cell transplant (SCT).

17. The method of claim 1 , wherein:

(a) the first and second dosing cycles are 21-day dosing cycles;

(b) glofitamab is administered intravenously; and/or

(c) polatuzumab vedotin is administered intravenously.

18. The method of claim 1 , wherein the subject:

(a) is human;

(b) has received at least two prior systemic therapies; and/or

(c) is ineligible for autologous stem cell transplant (SCT).

19. The method of claim 1 , wherein the method further comprises administering to the subject obinutuzumab.

20. The method of claim 19 , wherein obinutuzumab is administered:

(a) prior to administration of glofitamab; and/or

(b) as a single dose of about 1000 mg.

21. The method of claim 20 , wherein obinutuzumab is administered about seven days prior to administration of glofitamab.

22. The method of claim 1 , wherein the CD20-positive cell proliferative disorder is a B cell proliferative disorder.

23. The method of claim 22 , wherein the B cell proliferative disorder is a non-Hodgkin's lymphoma (NHL) or a central nervous system lymphoma (CNSL).

24. The method of claim 23 , wherein the NHL is:

(a) relapsed and/or refractory; and/or

(b) a diffuse-large B cell lymphoma (DLBCL), a follicular lymphoma (FL), a mantle cell lymphoma (MCL), a marginal zone lymphoma (MZL), a high-grade B cell lymphoma, a primary mediastinal (thymic) large B cell lymphoma (PMLBCL), a diffuse B cell lymphoma, or a small lymphocytic lymphoma.

25. The method of claim 22 , wherein the B cell proliferative disorder is relapsed and/or refractory.

26. The method of claim 1 , wherein the method further comprises administering to the subject one or more additional therapeutic agents.

27. The method of claim 2 , wherein the method further comprises administering to the subject one or more additional therapeutic agents.

28. The method of claim 11 , wherein the subjects:

(a) are human;

(b) have received at least two prior systemic therapies; and/or

(c) are ineligible for autologous stem cell transplant (SCT).

Assignments (14)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: CARLILE, DAVID JOHN
To: ROCHE PRODUCTS LIMITED
Reel/Frame 068514/0743 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: MORCOS, PETER NABIL
To: ROCHE TCRC, INC.
Reel/Frame 068514/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: DJEBLI, NASSIM
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 068514/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: LUNDBERG, LINDA MARIA
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 068515/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: ROCHE PRODUCTS LIMITED
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 068515/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: ROCHE TCRC, INC.
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 068515/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 068515/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2022
From: DIMIER, NATALIE
To: ROCHE PRODUCTS LIMITED
Reel/Frame 060953/0966 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2022
From: MOORE, THOMAS FRANCIS
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 060954/0207 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2022
From: ROCHE DIAGNOSTICS GMBH
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 060954/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2022
From: WEISSER, MARTIN
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 060954/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2022
From: LECHNER, KATHARINA
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 060955/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2022
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 060956/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2022
From: ROCHE PRODUCTS LIMITED
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 060958/0353 →
Priority Claims (1)
WO PCT/EP2021/080293 · Nov 2, 2021 · international
Continuity (2)
Provisional Application 63182749 · Apr 30, 2021
Related Publication 20220380480A1 · Dec 1, 2022
References Cited (351)
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5587458A · King et al. · 1996 [cited by applicant]
US 5591828A · Bosslet et al. · 1997 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 6248516B1 · Winter et al. · 2001 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6809185B1 · Schoonjans et al. · 2004 [cited by applicant]
US 7332581B2 · Presta · 2008 [cited by applicant]
US 7695936B2 · Carter et al. · 2010 [cited by applicant]
US 8227577B2 · Klein et al. · 2012 [cited by applicant]
US 8236308B2 · Kischel et al. · 2012 [cited by applicant]
US 8242247B2 · Klein et al. · 2012 [cited by applicant]
US 8642742B2 · Hofer et al. · 2014 [cited by applicant]
US 8703132B2 · Imhof-Jung et al. · 2014 [cited by applicant]
US 8709421B2 · Heiss et al. · 2014 [cited by applicant]
US 8796424B2 · Croasdale et al. · 2014 [cited by applicant]
US 8846042B2 · Zhou · 2014 [cited by applicant]
US 8895702B2 · Williams et al. · 2014 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9068008B2 · Mossner et al. · 2015 [cited by applicant]
US 9206260B2 · Hofer et al. · 2015 [cited by applicant]
US 9266938B2 · Ast et al. · 2016 [cited by applicant]
US 9266967B2 · Klein et al. · 2016 [cited by applicant]
US 9382323B2 · Brinkmann et al. · 2016 [cited by applicant]
US 9447159B2 · Ast et al. · 2016 [cited by applicant]
US 9526797B2 · Gerdes et al. · 2016 [cited by applicant]
US 9714291B2 · Niwa et al. · 2017 [cited by applicant]
US 9914776B2 · Ast et al. · 2018 [cited by applicant]
US 10357571B2 · Williams et al. · 2019 [cited by applicant]
US 10611840B2 · Ast et al. · 2020 [cited by applicant]
US 10611841B2 · Ast et al. · 2020 [cited by applicant]
US 20020004587A1 · Miller et al. · 2002 [cited by applicant]
US 20070071675A1 · Wu et al. · 2007 [cited by applicant]
US 20070111281A1 · Sondermann et al. · 2007 [cited by applicant]
US 20070219133A1 · Lazar et al. · 2007 [cited by applicant]
US 20080241152A1 · Alitalo et al. · 2008 [cited by applicant]
US 20090252683A1 · Kischel et al. · 2009 [cited by applicant]
US 20090304719A1 · Daugherty et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20100150918A1 · Kufer et al. · 2010 [cited by applicant]
US 20100316645A1 · Imhof-Jung et al. · 2010 [cited by applicant]
US 20110178279A1 · Williams et al. · 2011 [cited by applicant]
US 20110293613A1 · Brinkmann et al. · 2011 [cited by applicant]
US 20120225071A1 · Klein et al. · 2012 [cited by applicant]
US 20120276125A1 · Ast et al. · 2012 [cited by applicant]
US 20130022601A1 · Brinkmann et al. · 2013 [cited by applicant]
US 20130058936A1 · Bruenker et al. · 2013 [cited by applicant]
US 20130058937A1 · Auer et al. · 2013 [cited by applicant]
US 20130060011A1 · Bruenker et al. · 2013 [cited by applicant]
US 20130078249A1 · Ast et al. · 2013 [cited by applicant]
US 20130171095A1 · Bernett et al. · 2013 [cited by applicant]
US 20130266568A1 · Brinkmann et al. · 2013 [cited by applicant]
US 20140088295A1 · Smith et al. · 2014 [cited by applicant]
US 20140112914A1 · Nezu et al. · 2014 [cited by applicant]
US 20140154254A1 · Kannan et al. · 2014 [cited by applicant]
US 20140242079A1 · Bacac et al. · 2014 [cited by applicant]
US 20140242080A1 · Jaeger et al. · 2014 [cited by applicant]
US 20140288275A1 · Moore et al. · 2014 [cited by applicant]
US 20140294823A1 · Moore et al. · 2014 [cited by applicant]
US 20140294833A1 · Desjarlais et al. · 2014 [cited by applicant]
US 20140302064A1 · Moore · 2014 [cited by applicant]
US 20140322217A1 · Moore et al. · 2014 [cited by applicant]
US 20140363426A1 · Moore et al. · 2014 [cited by applicant]
US 20140370013A1 · Desjarlais et al. · 2014 [cited by applicant]
US 20140377270A1 · Moore et al. · 2014 [cited by applicant]
US 20150166661A1 · Chen et al. · 2015 [cited by applicant]
US 20150266966A1 · Smith et al. · 2015 [cited by applicant]
US 20150274845A1 · Bruenker et al. · 2015 [cited by applicant]
US 20150315296A1 · Schaefer et al. · 2015 [cited by applicant]
US 20150368351A1 · Vu et al. · 2015 [cited by applicant]
US 20150376287A1 · Vu et al. · 2015 [cited by applicant]
US 20160075785A1 · Ast et al. · 2016 [cited by applicant]
US 20160130347A1 · Bruenker et al. · 2016 [cited by applicant]
US 20160145354A1 · Bacac et al. · 2016 [cited by applicant]
US 20160152711A1 · Williams et al. · 2016 [cited by applicant]
US 20160159906A1 · Sun · 2016 [cited by examiner]
US 20160175397A1 · Umana et al. · 2016 [cited by applicant]
US 20160194399A1 · Irving et al. · 2016 [cited by applicant]
US 20160208017A1 · Ast et al. · 2016 [cited by applicant]
US 20160208019A1 · Bacac et al. · 2016 [cited by applicant]
US 20160263240A1 · Ast et al. · 2016 [cited by applicant]
US 20160297881A1 · Vu et al. · 2016 [cited by applicant]
US 20160368985A1 · Hotzel et al. · 2016 [cited by applicant]
US 20170008971A1 · Dennis et al. · 2017 [cited by applicant]
US 20170096485A1 · Bacac et al. · 2017 [cited by applicant]
US 20170096495A1 · Bacac et al. · 2017 [cited by applicant]
US 20170114146A1 · Klein et al. · 2017 [cited by applicant]
US 20170174786A1 · Bacac et al. · 2017 [cited by applicant]
US 20170190783A1 · Bacac et al. · 2017 [cited by applicant]
US 20170209573A1 · Bacac et al. · 2017 [cited by applicant]
US 20170218074A1 · Williams et al. · 2017 [cited by applicant]
US 20170253670A1 · Klein et al. · 2017 [cited by applicant]
US 20170267783A1 · Nezu et al. · 2017 [cited by applicant]
US 20170306018A1 · Vu et al. · 2017 [cited by applicant]
US 20170306036A1 · Vu et al. · 2017 [cited by applicant]
US 20170306044A1 · Vu et al. · 2017 [cited by applicant]
US 20170327579A1 · Vu et al. · 2017 [cited by applicant]
US 20170327580A1 · Vu et al. · 2017 [cited by applicant]
US 20180134798A1 · Chu · 2018 [cited by examiner]
US 20180148508A1 · Wang et al. · 2018 [cited by applicant]
US 20180193479A1 · Williams et al. · 2018 [cited by applicant]
US 20200164077A1 · Williams et al. · 2020 [cited by applicant]
US 20200172627A1 · Bacac · 2020 [cited by examiner]
US 20200199578A1 · Short et al. · 2020 [cited by applicant]
US 20200325238A1 · Bacac et al. · 2020 [cited by applicant]
US 20240132613A1 · Chu et al. · 2024 [cited by applicant]
CA 2853230A1 · 2013 [cited by applicant]
CA 2884307A1 · 2014 [cited by applicant]
CN 102369218A · 2012 [cited by applicant]
CN 102373214A · 2012 [cited by applicant]
CN 102892779A · 2013 [cited by applicant]
CN 103429737A · 2013 [cited by applicant]
CN 103748114A · 2014 [cited by applicant]
CN 103764681A · 2014 [cited by applicant]
CN 103889452A · 2014 [cited by applicant]
CN 104245738A · 2014 [cited by applicant]
CN 104640881A · 2015 [cited by applicant]
CN 105143258A · 2015 [cited by applicant]
CN 105934253A · 2016 [cited by applicant]
CN 106029696A · 2016 [cited by applicant]
CN 106164095A · 2016 [cited by applicant]
EP 0404097B1 · 1996 [cited by applicant]
EP 1870459A1 · 2007 [cited by applicant]
EP 1870459A4 · 2010 [cited by applicant]
EP 2578230A1 · 2013 [cited by applicant]
EP 2647707A1 · 2013 [cited by applicant]
EP 2647707A4 · 2014 [cited by applicant]
EP 1870459B1 · 2016 [cited by applicant]
EP 3177643B1 · 2019 [cited by applicant]
JP 2011508604A · 2011 [cited by applicant]
JP 2015509951A · 2015 [cited by applicant]
JP 2015509952A · 2015 [cited by applicant]
JP 2018527887A · 2018 [cited by applicant]
RU 2539112C2 · 2015 [cited by applicant]
SG 10201803384T · 2018 [cited by applicant]
TW 201508008A · 2015 [cited by applicant]
WO WO9103493A1 · 1991 [cited by applicant]
WO WO9301161A1 · 1993 [cited by applicant]
WO WO9316185A2 · 1993 [cited by applicant]
WO WO9601126A1 · 1996 [cited by applicant]
WO WO9627011A1 · 1996 [cited by applicant]
WO WO9640210A1 · 1996 [cited by applicant]
WO WO9850431A2 · 1998 [cited by applicant]
WO WO9850431A3 · 1999 [cited by applicant]
WO WO0209573A2 · 2002 [cited by applicant]
WO WO03074679A2 · 2003 [cited by applicant]
WO WO2005044859A2 · 2005 [cited by applicant]
WO WO2005083431A2 · 2005 [cited by applicant]
WO WO2006082515A2 · 2006 [cited by applicant]
WO WO2007005874A2 · 2007 [cited by applicant]
WO WO2007024715A2 · 2007 [cited by applicant]
WO WO2007042261A2 · 2007 [cited by applicant]
WO WO2007075270A2 · 2007 [cited by applicant]
WO WO2007110205A2 · 2007 [cited by applicant]
WO WO2007146968A2 · 2007 [cited by applicant]
WO WO2007147901A1 · 2007 [cited by applicant]
WO WO2007024715A3 · 2008 [cited by applicant]
WO WO2008119566A2 · 2008 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2007024715A9 · 2009 [cited by applicant]
WO WO2009070642A1 · 2009 [cited by applicant]
WO WO2009080251A1 · 2009 [cited by applicant]
WO WO2009080252A1 · 2009 [cited by applicant]
WO WO2009080253A1 · 2009 [cited by applicant]
WO WO2009080254A1 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2009106321A1 · 2009 [cited by applicant]
WO WO2010115589A1 · 2010 [cited by applicant]
WO WO2010129304A2 · 2010 [cited by applicant]
WO WO2010136172A1 · 2010 [cited by applicant]
WO WO2010145792A1 · 2010 [cited by applicant]
WO WO2010145793A1 · 2010 [cited by applicant]
WO WO2010129304A3 · 2011 [cited by applicant]
WO WO2011028945A1 · 2011 [cited by applicant]
WO WO2011028952A1 · 2011 [cited by applicant]
WO WO2011090754A1 · 2011 [cited by applicant]
WO WO2011090762A1 · 2011 [cited by applicant]
WO WO2011103242A1 · 2011 [cited by applicant]
WO WO2011121110A1 · 2011 [cited by applicant]
WO WO2011143545A1 · 2011 [cited by applicant]
WO WO2012025525A1 · 2012 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2012058768A8 · 2012 [cited by applicant]
WO WO2012073985A1 · 2012 [cited by applicant]
WO WO2012117002A1 · 2012 [cited by applicant]
WO WO2012130831A1 · 2012 [cited by applicant]
WO WO2012143524A2 · 2012 [cited by applicant]
WO WO2012158818A2 · 2012 [cited by applicant]
WO WO2012162067A2 · 2012 [cited by applicant]
WO WO2013012414A1 · 2013 [cited by applicant]
WO WO2013026831A1 · 2013 [cited by applicant]
WO WO2013026832A1 · 2013 [cited by applicant]
WO WO2013026833A1 · 2013 [cited by applicant]
WO WO2013026837A1 · 2013 [cited by applicant]
WO WO2013026839A1 · 2013 [cited by applicant]
WO WO2013096291A2 · 2013 [cited by applicant]
WO WO2013128027A1 · 2013 [cited by applicant]
WO WO2013128194A1 · 2013 [cited by applicant]
WO WO2013150043A1 · 2013 [cited by applicant]
WO WO2013157953A1 · 2013 [cited by applicant]
WO WO2013157954A1 · 2013 [cited by applicant]
WO WO2014022540A1 · 2014 [cited by applicant]
WO WO2014028560A2 · 2014 [cited by applicant]
WO WO2014039855A1 · 2014 [cited by applicant]
WO WO2014047231A1 · 2014 [cited by applicant]
WO WO2014054804A1 · 2014 [cited by applicant]
WO WO2014056783A1 · 2014 [cited by applicant]
WO WO2014028560A3 · 2014 [cited by applicant]
WO WO2014081955A1 · 2014 [cited by applicant]
WO WO2014122143A1 · 2014 [cited by applicant]
WO WO2014122144A1 · 2014 [cited by applicant]
WO WO2014122251A2 · 2014 [cited by applicant]
WO WO2014141152A2 · 2014 [cited by applicant]
WO WO2014144722A2 · 2014 [cited by applicant]
WO WO2014150877A1 · 2014 [cited by applicant]
WO WO2014153002A1 · 2014 [cited by applicant]
WO WO2014122251A3 · 2014 [cited by applicant]
WO WO2014167022A1 · 2014 [cited by applicant]
WO WO2014141152A3 · 2014 [cited by applicant]
WO WO2014191113A1 · 2014 [cited by applicant]
WO WO2014210064A1 · 2014 [cited by applicant]
WO WO2014191113A8 · 2015 [cited by applicant]
WO WO2015095392A1 · 2015 [cited by applicant]
WO WO2015095418A1 · 2015 [cited by applicant]
WO WO2015150447A1 · 2015 [cited by applicant]
WO WO2016019969A1 · 2016 [cited by applicant]
WO WO2016020065A1 · 2016 [cited by applicant]
WO WO2016020309A1 · 2016 [cited by applicant]
WO WO2016020332A1 · 2016 [cited by applicant]
WO WO2016036678A1 · 2016 [cited by applicant]
WO WO2016055592A1 · 2016 [cited by applicant]
WO WO2016055593A1 · 2016 [cited by applicant]
WO WO2016079081A1 · 2016 [cited by applicant]
WO WO2016079177A1 · 2016 [cited by applicant]
WO WO2016081490A1 · 2016 [cited by applicant]
WO WO2016087531A1 · 2016 [cited by applicant]
WO WO2016090210A1 · 2016 [cited by applicant]
WO WO2016110576A1 · 2016 [cited by applicant]
WO WO2016179003A1 · 2016 [cited by applicant]
WO WO2016205520A1 · 2016 [cited by applicant]
WO WO2017021450A1 · 2017 [cited by applicant]
WO WO2018093821A1 · 2018 [cited by applicant]
WO WO2019095641A1 · 2019 [cited by applicant]
WO WO2022098648A2 · 2022 [cited by applicant]
Hutchings et al. (Blood, 136: 46-48, Nov. 5, 2020). [cited by examiner]
Djebli et al. (Blood, 136 (Supplement 1), 2020). [cited by examiner]
“Purified Mouse Anti-Human CD3-epsilon Clone SP34,” BD Biosciences, <https://www.bdbiosciences.com/us/reagents/research/antibodies-buffers/immunology-reagents/anti-non-human-primate-antibodies/cell-surface-antigens/puri… [cited by applicant]
Atwell et al., “Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library,” J Mol Biol. 270(1):26-35 (1997). [cited by applicant]
BBE23702, GenomeQuest Keyword Search Report, dated May 1, 2017 (2 pages). [cited by applicant]
BBE23705, GenomeQuest Keyword Search Report, dated May 1, 2017 (2 pages). [cited by applicant]
BBF28771, GenomeQuest Keyword Search Report, dated May 1, 2017 (2 pages). [cited by applicant]
BBF28775, GenomeQuest Keyword Search Report, dated May 1, 2017 (2 pages). [cited by applicant]
Beckman et al., “Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors,” Cancer. 109(2):170-9 (2007). [cited by applicant]
Booy et al., “Monoclonal and bispecific antibodies as novel therapeutics,” Arch Immunol Ther Exp (Warsz). 54(2):85-101 (2006). [cited by applicant]
Bosch et al., “MCSP/CD3-bispecific single-chain antibody construct engages CD4+ and CD8+ T cells for lysis of MCSP-expressing human uveal melanoma cells,” AACR 101st Annual Meeting. Apr. 17-21, Washington, DC. 70(8 Supp… [cited by applicant]
Budde et al., “Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study,” B… [cited by applicant]
Budde et al., “Ongoing Phase 1B/2 Trials of Mosunetuzumab Investigating Novel Treatment Regimens for Patients with B-Call Non-Hodgkin Lymphoma (NHL),” Hematol Oncol. 37(52):564-566 (2019) (4 pages). [cited by applicant]
Buhmann et al., “Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion,” Bone Marrow Transplant. 43(5):383-97 (2009… [cited by applicant]
Buhmann et al., “Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transp… [cited by applicant]
Carter, “Bispecific human IgG by design,” J Immunol Methods. 248(1-2):7-15 (2001). [cited by applicant]
Chan et al., “Variable region domain exchange in human IgGs promotes antibody complex formation with accompanying structural changes and altered effector functions,” Mol Immunol. 41(5):527-38 (2004). [cited by applicant]
Conaghan et al., “Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen,” Br J Cancer. 98(7):1217-25 (2008). [cited by applicant]
Desnoyers et al., “Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index,” Sci Transl Med. 5(207):207ra144 (2013) (2 pages) (Abstract only). [cited by applicant]
Diefenbach et al., “An individualized risk mitigation approach for safety: experience from the mosunetuzumab (CD20/CD3 bispecific antibody) development program in relation to neurotoxicity risk,” 61st Ash Annual Meeting… [cited by applicant]
Donaldson et al., “Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies,” available in PMC Jan. 16, 2013, published in final edited form as: Cancer Bio… [cited by applicant]
Edelman et al., “The covalent structure of an entire gammaG immunoglobulin molecule,” Proc Natl Acad Sci U S A. 63(1):78-85 (1969). [cited by applicant]
Edwards et al., “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS,” J Mol Biol. 334(1):103-18 (2003). [cited by applicant]
Erster et al., “Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases,” J Control Release.161(3): 804-12 (2012) (2 pages) (Abstract only). [cited by applicant]
Gaston et al., “Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions,” Sci Rep. 9(1):18688 (2019) (12 pages). [cited by applicant]
Ghosh et al., “Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Di… [cited by applicant]
Gonzales et al., “Minimizing the Immunogenicity of Antibodies for Clinical Application,” Tumor Biol. 26(1):31-43 (2005) (Abstract only) (1 page). [cited by applicant]
Haile et al., “Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression,” J Immunol. 191(5):2829-36 (2013) (9 pages). [cited by applicant]
Han et al., “Masked Chimeric Antigen Receptor for Tumor-Specific Activation,” Mol Ther. 25(1):274-84 (2017). [cited by applicant]
Hernandez et al., “Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma,” Blood. 134(Supplement 1):1585 (2019) (4 pag… [cited by applicant]
Holliger et al., “Diabodies': small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci U S A. 90(14):6444-8 (1993). [cited by applicant]
Holliger et al., “Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody,” Protein Eng. 9(3):299-305 (1996). [cited by applicant]
Honeychurch et al., “Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome,” Cancer Immunol Immunother. 45(3-4):171-3 (1997). [cited by applicant]
Hosseini et al., “Abstract B043: Systems pharmacology modeling of anti-CD20/CD3 T-cell dependent bispecific antibody and its application to clinical trial design,” Proceedings of the Second CRI-CIMT-EATI-AACR Internatio… [cited by applicant]
Hosseini et al., “Mitigating The Risk Of Cytokine Release Syndrome In A Phase I Trial Of CD20/CD3 Bispecific Antibody Mosunetuzumab In NHL: Impact Of Translational System Modeling,” NPJ Syst Biol Appl. 6(1):28 (2020) (1… [cited by applicant]
Huang, “Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis,” Pharmacol Ther. 86(3):201-215 (2000). [cited by applicant]
Hudson et al., “Engineered antibodies,” Nat Med. 9(1):129-34 (2003). [cited by applicant]
Hutchings et al., “Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Ly… [cited by applicant]
Hutchings et al., “Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial,” J Clin Oncol. 39(18):… [cited by applicant]
Jaksic et al., “High Dose Chlorambucil versus Binet's Modified Cyclophosphamide Doxorubicin, Vincristine, and Prednisone Regimen in the Treatment of Patients with Advanced B-Cell Chronic Lymphocytic Leukemia. Results of… [cited by applicant]
Kipriyanov et al., “Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics,” J Mol Biol. 293(1):41-56 (1999). [cited by applicant]
Klein et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” MAbs. 4(6):653-63 (2012). [cited by applicant]
Kontermann, “Dual targeting strategies with bispecific antibodies,” MAbs. 4(2):182-97 (2012). [cited by applicant]
Leabman et al., “Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys,” MAbs. 5(6):896-903 (2013). [cited by applicant]
Lee et al., “Current concepts in the diagnosis and management of cytokine release syndrome,” Blood. 124(2):188-95 (2014) (18 pages). [cited by applicant]
Li et al., “Exposure-response analyses indicate a promising benefit/risk profile of mosunetuzumab in relapsed and refractory non-Hodgkin lymphoma,” 61st Ash Annual Meeting & Exposition (2019) (1 page). [cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens”. Protein Eng Des Sel. 22(3):159-68 (2009). [cited by applicant]
Lord et al., “Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFß1 antibody,” MAbs. 10(3):444-452 (2018) (10 pages). [cited by applicant]
Lu et al., “Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma,” Biochem Biophys Res Commun. 473(4):808-813 (2016) (Abstract only) (3 pages). [cited by applicant]
Lund et al., “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” J Immunol. 157(11… [cited by applicant]
MacLean et al., “Anti-CD3:anti-IL-2 receptor-bispecific mAb-mediated immunomodulation. Low systemic toxicity, differential effect on lymphoid tissue, and inhibition of cell-mediated hypersensitivity,” J Immunol. 155(7):… [cited by applicant]
Mariuzza et al., “The structural basis of antigen-antibody recognition,” Annu Rev Biophys Biophys Chem. 16:139-159 (1987) (2 pages) (Abstract only). [cited by applicant]
Merchant et al., “An efficient route to human bispecific IgG,” Nat Biotechnol. 16(7):677-81 (1998). [cited by applicant]
Miller et al., “Design, construction, and in vitro analyses of multivalent antibodies,” J Immunol. 170(9):4854-61 (2003). [cited by applicant]
Milne et al., “Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors,” PLoS One. 4(7):e6412 (2009) (14 pages). [cited by applicant]
Minson et al., “Trial in Progress: A Multicentre, Parallel Arm, Open-Label Trial of Frontline R-CHOP/Polatuzumab Vedotin-RCHP and Glofitamab in Younger Patients with Higher Risk Diffuse Large B Cell Lymphoma (Coalition)… [cited by applicant]
Montoto et al., “Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,” J Clin Oncol. 25(17):2426-33 (2007) (9 pages). [cited by applicant]
Moore et al., “A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens,” MAbs. 3(6):546-57 (2011). [cited by applicant]
Moore et al., “Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma,” Blood. 117(17):4542-51 (2011) (11 pages). [cited by applicant]
Nagorsen et al., “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Exp Cell Res. 317(9):1255-60 (2011). [cited by applicant]
NIH/NCI, “anti-PD-1 fusion protein AMP-224,” dated Jul. 10, 2015, accessed Jul. 31, 2019 (1 page). [cited by applicant]
Nishimoto et al., “Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study,” J Rheumatol.… [cited by applicant]
Oshimi et al., “Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody,” Blood. 77(5):1044-9 (1991) (7 pages). [cited by applicant]
Paino et al., “Reply to ‘Response to ’CD20 Positive Cells Are Undetectable in the Majority of Multiple Myeloma Cell Lines and Are Not Associated With a Cancer Stem Cell Phenotype,” Haematologica. 97(7):1110-1114 (2012) … [cited by applicant]
Peng et al., “The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA,” PLoS One. 7(5):e36412 (2012) (14 pages). [cited by applicant]
Pessano et al., “The T3/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-delta and T3-epsilon) subunits,” EMBO J. 4(2):337-44 (1985). [cited by applicant]
Plückthun, Chapter 11: Antibodies from [cited by applicant]
Polu et al., “Probody therapeutics for targeting antibodies to diseased tissue,” Expert Opin Biol Ther. 14(8):1049-53 (2014). [cited by applicant]
Reusch et al., “Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model,” Clin Cancer Res. 12(1):183-90 (2… [cited by applicant]
Ridgway et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Eng. 9(7):617-21 (1996). [cited by applicant]
Riedle et al., “In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice,” Int J Cancer. 75(6):908-18 (1998). [cited by applicant]
Rudnick et al., “Affinity and avidity in antibody-based tumor targeting,” Cancer Biother Radiopharm. 24(2):155-61 (2009). [cited by applicant]
Salmerón et al., “A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies,” J Immunol. 147(9): 3047-52 (… [cited by applicant]
Schaefer et al., “Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies,” Proc Natl Acad Sci U S A. 108(27):11187-92 (2011). [cited by applicant]
Schuster et al., “Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies,” Br J Haematol. 169:90-102 (2015… [cited by applicant]
Seimetz et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy,” Cancer Treat Rev. 36(6):458-67 (2010). [cited by applicant]
Sen et al., “Use of Anti-CD3 x Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu [cited by applicant]
Seung et al., “Immunotherapy with long-lived anti-CD20 x anti-CD3 bispecific antibodies stimulates potent t cell-mediated killing of human b cell lines and of circulating and lymphoid b cells in monkeys: a potential the… [cited by applicant]
Shi et al., “Margin-Infiltrating CD20 [cited by applicant]
Somasundaram et al., “Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?” Mol Ther. 19(4):638-40 (2011). [cited by applicant]
Stein et al., “Novel and Emerging Drugs for Acute Myeloid Leukemia,” available in PMC May 22, 2014, published in final edited form as: Curr Cancer Drug Targets. 12(5):522-530 (2012) (19 pages). [cited by applicant]
Stewart et al., “Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen,” Cancer Immunol Immunother. 47(6):299-306 (1999). [cited by applicant]
Stieglmaier et al., “Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer,” Expert Opin Biol Ther. 15(8):1093-1099 (2015) (8 pages). [cited by applicant]
Stubenrauch et al., “Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys,” Drug Metab Dispos. 38(1):84-91 (2010). [cited by applicant]
Sun et al., “Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies,” Sci Transl Med. 7(287):287ra70 (2015) (11 pages). [cited by applicant]
Torisu-Itakura et al., “Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells,” J Immunother. 34(8):597-605 (2011). [cited by applicant]
Trabolsi et al., “T Cell-Activating Bispecific Antibodies in Cancer Therapy,” J Immunol. 203(3):585-592 (2019) (9 pages). [cited by applicant]
Tutt et al., “Trispecific F(ab') [cited by applicant]
Wakefield et al., “Addition of a C-terminal extension sequence to transforming growth factor-beta 1 interferes with biosynthetic processing and abolishes biological activity,” Growth Factors. 5(3):243-53 (1991) (2 pages… [cited by applicant]
Wells et al., “Reaching for high-hanging fruit in drug discovery at protein-protein interfaces,” Nature. 450(7172):1001-9 (2007). [cited by applicant]
Wolf et al., “BiTEs: bispecific antibody constructs with unique anti-tumor activity,” Drug Discov Today. 10(18):1237-44 (2005). [cited by applicant]
Wu et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J Mol Biol. 294(1):151-162 (1999). [cited by applicant]
Yang et al., “Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency,” MAbs. 7(2):440-50 (2015). [cited by applicant]
Yu et al., “Interaction between bevacizumab and murine VEGF-A: a reassessment,” Invest Ophthalmol Vis Sci. 49(2):522-7 (2008). [cited by applicant]
Zhu et al., “Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation,” J Immunol. 155(4):1903-10 (1995). [cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Patent Application No. 17808689.8, dated Apr. 30, 2020 (8 pages). [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/EP2021/080293, dated Feb. 10, 2022 (65 pages). [cited by applicant]
“History of Changes for Study: NCT02500407: A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocy… [cited by applicant]
Chu et al., “Immunotherapy with long-lived anti-CD20 x anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of Human B cell lines and of circulating and lymphoid B cells in monkeys: a potential thera… [cited by applicant]
Heini et al., “Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma,” Cells 11(17):2747 (Sep. 2022) (12 pages). [cited by applicant]
Hutchings et al., “Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in … [cited by applicant]
Hutchings et al., “Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma” Blood. 136(Supplement 1):46, Nov. 5, 2020, (6 pages). [cited by applicant]
Xiong et al., “Study of specific targeting cytotoxicity mediated by anti-CD3/anti-CD [cited by applicant]
Xu et al., “Production of bispecific antibodies in ‘knobs-into-holes’ using a cell-free expression system,” [cited by applicant]
Yuraszeck et al., “A quantitative systems pharmacology (QSP) model to assess the action of blinatumomab in NHL patients (pts),” Journal of Clinical Oncology 34(15_suppl) Abstract e14511 (May 20, 2016) (3 pages). [cited by applicant]